Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV
Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan
Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta®
Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus
Ligand Provides Highlights from Today’s Analyst Day Event
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag)
Ligand Reports Third Quarter 2014 Financial Results
Ligand to Host Analyst Day on November 18th in New York City
Ligand Reports Third Quarter Revenues and Expected Diluted EPS
Ligand Earns Milestone Payment Triggered by EU Approval of Merck’s Captisol-enabled NOXAFIL® (posaconazole) Concentrate for Solution for Infusion
Ligand Licenses Captisol-enabled™ Lamotrigine to CURx Pharmaceuticals, Inc.
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in Patients with Severe Aplastic Anemia
Ligand Signs Multi-Program Captisol® License Agreement with Avion Pharmaceuticals
Ligand Prices Offering of $225 Million of Convertible Senior Notes
